NGENLA (Pfizer Australia Pty Ltd)
Product name
NGENLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
182 (255 working days)
Active ingredients
somatrogon
Registration type
NCE/NBE
Indication
NGENLA (solution for injection) is indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.